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Abstract. Abiraterone provides significant survival 
advantages in prostate cancer (PC), however, the current 
understanding of the molecular mechanisms of abiraterone is 
still limited. Therefore, the abiraterone impact on androgen 
receptor (AR)-positive LNCaP and AR-negative PC-3 cells 
was assessed by cellular and molecular analyses. The present 
study demonstrated, that abiraterone treatment significantly 
decreased cell growth, AR expression, and AR activity of 
AR-positive LNCaP cells. Notably, AR-negative PC-3 cells 
exhibited comparable reductions in cellular proliferation, 
associated with DNA fragmentation and pro-apoptotic 
modulation of p21, caspase-3, survivin, and transforming 
growth factor β (TGFβ). Our observations suggest that the 
attenuation of AR signaling is not the only rationale to 
explain the abiraterone anticancer activity. Abiraterone effi-
cacy may play a more global role in PC progression control 
than originally hypothesized. In this regard, abiraterone is 
not only a promising drug for treatment of AR-negative PC 
stages, even more, abiraterone may represent an alternative 
for treatment of other malignancies besides prostate cancer.
Introduction
Molecular factors involved in the progression of advanced 
prostate cancer (PC), from an initially well responding state 
to a castration-resistant tumor, are multifunctional but can 
be attributed to the capability of cell proliferation in a low 
androgen environment. Castration-resistant PC is clinically 
reflected by rising levels of prostate specific antigen (PSA) and 
predominantly driven by changes in androgen receptor (AR) 
signaling. Phenotypical alterations in AR functionality enable 
tumor cell growth in absence or with near undetectable concen-
trations of androgens. Current studies suggest that initiation 
and progression of PC are tightly driven by local de novo 
synthesis of androgens in tumor tissue and tumor environment 
and accessorily accompanied by extragonadal sources, as the 
conversion of circulating steroid precursors to testosterone and 
dihydrotestosterone (1,2).
Within the group of new generation PC drugs, abiraterone 
was shown to provide significant survival advantages with 
modest toxicity even in post-chemotherapy settings (3). 
Abiraterone elicits antitumor activity by inhibiting cyto-
chrome P450, family 17, subfamily A, polypeptide 1 
(CYP17A1) enzyme, which is critical for steroid synthesis 
from cholesterol. CYP17A1 studies by conversion of both 
pregnenolone and progesterone to 17α-hydroxypregnenolone 
and 17α-hydroxyprogesterone (17α-hydroxylase activity) 
and by subsequent cleavage of 17α-hydroxypregnenolone 
and 17α-hydroxyprogesterone to dehydroepiandrosterone 
(DHEA) and androstenedione (C17,20-lyase activity) (4). 
Although less efficient than CYP17A1 inhibition, abiraterone 
also blocks some downstream enzymes of the steroid 
pathway (5). Additionally to blockading steroid hormones, 
the derangement of steroidogenic biosynthesis lowers the 
concentration of glucocorticoids and results in exaggerated 
production of mineralocorticoids (6). Moreover, clinical and 
preclinical studies have shown that abiraterone possesses 
further activities which may contribute to tumor biology 
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of advanced PC. Most likely based on its steroidal struc-
ture, abiraterone has been found bound to the AR and thus 
competitively antagonizes subsequent AR signaling cascades, 
however, not as potent as pure antagonists, e.g. bicalu-
tamide (7,8). On the contrary, there are lines of evidence that 
abiraterone is an inducer of steroidogenic enzymes including 
CYP17A1 and may increase expression of steroid synthesis 
machinery (9-11). Our present understanding of molecular 
properties of abiraterone is still limited. In particular, combi-
natorial or sequential combinations of abiraterone with other 
drugs as well as the usage of abiraterone in different settings 
of PC remain unsolved. Due to multiplicity and complexity of 
recently described abiraterone effects, an inhibitory activity 
exclusively based on a blockade of androgen synthesis appears 
unlikely. With this study we assessed abiraterone effects on 
AR-positive and AR-negative PC cells to gain insight into the 
molecular mode of action.
Materials and methods
Chemicals and antibodies. Abiraterone acetate was kindly 
provided by Janssen-Cilag GmbH (Neuss, Germany) and was 
used as a 10 mM (LNCaP cells) and 30 mM (PC-3 cells) stock 
solution, respectively, with dimethyl sulfoxide (Carl Roth, 
Karlsruhe, Germany) as solvent. Docetaxel was purchased 
from Sigma-Aldrich (Munich, Germany) and was used as 
10 µM stock solution. Antibodies directed against the AR and 
the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
well as peroxidase-coupled secondary antibodies directed 
against mouse and rabbit were purchased from Cell Signaling 
Technology (Danvers, MA, USA). Antibodies specific for 
the transforming growth factor β (TGFβ) receptor type I 
and II were obtained from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA) and antibodies directed against 
homolog of Caenorhabditis Sma and Drosophila Mad 3 
(Smad3) and Smad4 were obtained from Zymed Laboratories 
(San Francisco, CA, USA).
Cell culture. The PC cell lines LNCaP and PC-3 from Cell 
Lines Service (CLS, Heidelberg, Germany) were propagated 
in RPMI-1640 media supplemented with 10% fetal bovine 
serum, 1% sodium pyruvate, and 1% penicillin/streptomycin 
(all from PAN Biotech, Aidenbach, Germany) at 5% CO2 
atmosphere and 37˚C. Cells were passaged twice per week 
using a trypsin/ethylenediaminetetraacetic acid solution 
(0.1/0.04%) dissolved in phosphate-buffered saline (PBS) 
(both from PAN Biotech). For experiments, cells were plated in 
poly-L-lysine (Sigma-Aldrich, Deisenhofen, Germany)-coated 
24-well (proliferation assay) and 6-well [quantitative reverse 
transcription-polymerase chain reaction (RT-PCR), western 
blot analysis] cell culture plates, respectively.
Proliferation assay. Cell growth of abiraterone treated cells 
was examined by cell counting utilizing a CASY Cell Counter 
and Analyzer Model TT (Roche Applied Science, Mannheim, 
Germany) and compared to vehicle treated cells. Therefore, 
30,000 cells/well were seeded in 24-well cell culture plates and 
treated as indicated. Number of living cells was determined by 
trypsin/ethylenediaminetetraacetic acid detachment of adherent 
cells and subsequent analysis. The cell suspension (100 µl) was 
diluted in 10,000 µl CASYton (Roche Applied Science) and 
analysis of 400 µl dilution was performed in triplicates using a 
capillary of 150 µm in diameter. Gate settings of 7.20/15.45 µm 
were used to ensure the discrimination between living cells 
and dead cells, as well as cellular debris.
Annexin V assay. Apoptosis detection of abiraterone-incubated 
PC-3 cells was performed using a FITC Annexin V Apoptosis 
Detection kit I (BD Bioscience, Heidelberg, Germany) as 
recommended by supplier instructions. After washing the cells 
once with PBS, 6x105-1x106 cells were harvested with a cell 
scraper and were resuspended in 1 ml PBS. After centrifuga-
tion and discarding the supernatant, the pellet was resuspended 
in binding buffer and stained with propidium iodide and FITC 
Annexin V for 15 min. Data were assessed by a FACSCanto A 
Cytometer and were analyzed using BD FACSDiva™ software 
(both from BD Bioscience).
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay. TUNEL apoptosis analysis of 
abiraterone-incubated PC-3 cells was performed using 
the HT TiterTACS assay kit (Trevigen, Gaithersburg, MD, 
USA) following supplier recommendations. After indicated 
time-points of incubation adherent cells were detached by 
0.1% trypsin/0.04% EDTA. Data were acquired using an 
Infinite 200 PRO multimode reader and were analyzed using 
the i-control 1.9 software (both from Tecan, Männedorf, 
Switzerland). Unlabeled and nuclease treated samples served 
as negative and positive control, respectively.
Quantitative RT-PCR. Total RNA was extracted using 500 µl 
peqGold TriFast reagent (PeqLab, Erlangen, Germany) and 
50 µl 1-bromo-3-chloropropane (Sigma-Aldrich) according to 
manufacturer's instructions. Prepared RNA was resuspended in 
diethyl pyrocarbonate (Carl Roth) treated water and RNA 
concentration was determined in a spectral photometer 
(NanoDrop 2000c; Peqlab). One microgram of total RNA was 
applied in RT using MMLV Reverse Transcriptase (Promega, 
Mannheim, Germany), Ribolock RNAse Inhibitor (Thermo 
Fisher Scientific, Rockford, IL, USA) and an oligo(dT)18 oligo-
nucleotide. Subsequently, mRNA amounts were quantified by 
real-time PCR using the following pairs of oligonucleotides: 
PSA forward, 5'-CCGGAGAGCTGTGTCACCAT-3' and 
reverse, 5'-GTGCAGCACCAATCCACGTC-3'; caspase-3 
forward, 5'-GCTCCTAGCGGATGGGTGCT-3' and reverse, 
5'-GATTCCAAGGCGACGCCAAC-3'; cyclin-dependent 
kinase inhibitor 1 (p21) forward, 5'-TGGAGACTCTCAGGGT 
CGAAA-3' and reverse, 5'-GGCGTTTGGAGTGGTAGAA 
ATC-3', Bcl-2-associated X protein (Bax) forward, 5'-TCC 
CCCCGAGAGGTCTTTT-3' and reverse, 5'-CGGCCCCA 
GTTGAAGTTG-3'; survivin forward, 5'-TGCCCCGACGT 
TGCC-3' and reverse, 5'-CAGTTCTTGAATGTAGAGATGC 
GGT-3', ribosomal protein large P0 (RPLP0) forward, 
5'-CAATGGCAGCATCTACAACC-3' and reverse, 5'-ACT 
CTTCCTTGGCTTCAACC-3'. Real-time PCR was carried out 
with SensiMix SYBR Hi-Rox (Bioline, Luckenwalde, 
Germany) in a CFX96 Real-Time PCR detection system 
(Bio-Rad Laboratories, München, Germany). For quantifica-
tion, target specific signals were standardized to RPLP0 mRNA 
as reference.
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Western blot analysis. Cells were lysed in buffer containing 
50 mM Tris (pH 7.5), 150 mM NaCl, 10 mM K2HPO4, 
5 mM EDTA, 10% glycerol, 1% Triton X-100, 0.05% sodium 
dodecyl sulfate, 1 mM Na3VO4, 20 mM NaF, 0.1 mM phenyl-
methylsulfonyl fluoride, 20 mM 2-phosphoglycerate, and 
complete protease inhibitor cocktail (Roche Applied Science), 
total amount of protein was determined by using Bradford 
reagent (12), and equal amounts of protein were conducted 
to gel electrophoresis. After transfer onto a nitrocellulose 
membrane (GE Healthcare Europe, Freiburg, Germany) and 
blocking (Roti-Block; Carl Roth), protein detection was done 
by incubation with target specific primary antibodies followed 
by species specific secondary antibodies and visualized by 
SuperSignal West Dura Chemiluminescent Substrate (Thermo 
Fisher Scientific) in a ChemiDoc XRS System (Bio-Rad 
Laboratories). Protein signals were quantified by Image 
Lab 3.0 software (Bio-Rad Laboratories) and standardized to 
GAPDH signals as reference.
Statistical analysis. Results of at least three independent exper-
iments were statistically analyzed. Analysis was performed 
using the Student's t-test with P≤0.05, P≤0.01 and P≤0.001 
given as significant. Data are expressed as mean ± SD.
Results
Cellular growth of AR-positive and hormone-sensitive LNCaP 
cells is attenuated in the presence of abiraterone by dimin-
ishing AR expression and activity. To investigate the effects of 
abiraterone on cellular growth of PC cells, AR-positive LNCaP 
cells were propagated in the presence of various concentra-
tions of abiraterone, ranging from 4 to 30 µM. We found 
abiraterone diminished cellular growth in a concentration-
dependent manner compared to vehicle treated control cells. 
At intermediate dosage of 10 µM abiraterone, cell proliferation 
was inhibited to ~50% after an exposure of 120 h (Fig. 1A). To 
verify theses data, growth kinetics of cells treated with 10 µM 
abiraterone were done and statistical analysis revealed that 
growth suppression was significant (72 h, 1.5-fold, P=0.0082; 
120 h, 1.5-fold, P=0.0010) (Fig. 1B). Subsequent western blot 
analysis of the AR expression after 72 h lasting abiraterone 
incubation showed significantly reduced levels of AR protein 
(24 h, 0.13±0.09, P<0.0001; 48 h, 0.20±0.10, P<0.0001; 72 h, 
0.16±0.10, P=0.0001) (Fig. 2A). The downregulation was 
accompanied by strongly attenuated transcriptional activity of 
the AR (24 h, 0.12±0.12, P=0.0096; 48 h, 0.06±0.04, P<0.0001; 
Figure 1. Abiraterone (AA) treatment attenuates cell growth of AR-positive 
LNCaP cells. (A) LNCaP cell were treated with vehicle or with concen-
trations of 4, 10, 20 and 30 µM abiraterone and proliferation assays were 
performed after indicated times of incubation. Columns, mean; bars, ± SD; 
*P≤0.05, **P≤0.01 and ***P≤0.001 (compared to vehicle treated control cells). 
(B) LNCaP cells were treated with vehicle or with 10 µM abiraterone for a 
period of time of 120 h and proliferation assays were performed after indi-
cated times of incubation. Boxes, mean; bars, ±SD; *P≤0.05, **P≤0.01 and 
***P≤0.001 (total number of living cells). 
Figure 2. Abiraterone suppresses AR expression and activity in LNCaP cells. 
(A) LNCaP cells were treated with vehicle or with 10 µM abiraterone for the 
indicated duration and total cell extracts were subjected to western blot anal-
yses to quantify AR protein expression normalized to GAPDH as internal 
reference. Columns, mean; bars, ± SD; *P≤0.05, **P≤0.01 and ***P≤0.001 
(compared to vehicle treated control cells). (B) LNCaP cells were treated with 
vehicle or with 10 µM abiraterone for the indicated duration. AR activity was 
assessed by quantification of the AR-dependent PSA mRNA transcription 
performing quantitative RT-PCR with RPLP0 mRNA as internal reference. 
Columns, mean; bars, ± SD; *P≤0.05, **P≤0.01 and ***P≤0.001 (compared to 
vehicle treated control cells).
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72 h, 0.05±0.03, P<0.0001) (Fig. 2B), which was measured by 
RT-PCR quantification of the AR-dependent PSA mRNA 
levels.
Abiraterone inhibits cellular growth of hormone-independent 
PC-3 cells lacking AR. It was commonly hypothesized that 
abiraterone inhibits androgen biosynthesis and AR signaling, 
which is the primary antitumor activity of the drug. However, 
participation of AR protein and AR properties in the molec-
ular mode of action of abiraterone have not been extensively 
investigated. Therefore, AR-negative PC-3 cells treated with 
10 to 40 µM abiraterone were analyzed and, very notably, 
presented growth inhibitory effects (Fig. 3A) comparable to 
AR-positive LNCaP cells. Further growth kinetics over 120 h 
showed statistically significant reductions of PC-3 prolifera-
tion treated with 30 µM abiraterone (48 h, 1.7-fold, P=0.0026; 
72 h, 2.3-fold, P<0.0001; 96 h, 2.8-fold, P<0.0001; 120 h, 
2.4-fold, P<0.0001) (Fig. 3B).
Abiraterone treatment of PC-3 cells initiates apoptosis due 
to modulation of pivotal factors in proliferation, apoptosis, 
and cell cycle regulation. To confirm whether the reduction 
of cell numbers after CAP treatment is the result of apoptotic 
cell death, we further examined the effects of CAP treatment 
by Annexin V and TUNEL assay. Previous experiments 
pointed to the fact that abiraterone-mediated attenuation of 
cellular growth can be obtained in the absence of the AR and 
AR-dependent signaling cascades. Therefore, we postulated 
interference with further regulatory pathways which may be 
critical for the abiraterone molecular mode of action. Primarily, 
we attempted to clarify whether abiraterone-dependent reduc-
tion of PC cell numbers could be associated with apoptotic cell 
death. Annexin V analysis in AR-negative PC-3 cells revealed 
a 1.09-fold and a 1.13-fold increase of apoptotic cells after 4 
and 24 h following abiraterone treatment (Fig. 4A) compared 
to vehicle treated controls. We detected a 1.86-fold and a 
1.93-fold increase of dead cells after 4 and 48 h following 
abiraterone treatment (Fig. 4B). Due to the ambiguity of the 
results, we enforced further apoptosis detection by TUNEL 
assay. DNA fragment labelling by TUNEL assay showed a 
significant increase of DNA fragmentation in abiraterone 
treated PC-3 cells after 24 and 72 h (24 h, 1.78±0.40, P=0.0290; 
72 h, 3.55±1.04, P=0.0133) (Fig. 4C). This was comparable to 
DNA fragmentation of docetaxel treated control cells (24 h, 
1.67±0.10, P=0.0005) (Fig. 4C).
In order to shed further light on the molecular mechanisms 
involved in abiraterone-induced attenuation of cell growth, we 
assessed the modulation of factors especially in apoptosis and 
cell cycle control. As shown by western blot analysis, signaling 
cascades of the cell growth controlling pleiotropic factor TGFβ 
were affected. Exposure of PC-3 cells to 30 µM abiraterone 
significantly inhibited protein expression of both TGFβ 
receptor isoforms, TGFβ receptor type I (24 h, 0.52±0.43, 
P=0.0152; 48 h, 0.44±0.18, P=0.0009; 72 h, 0.49±0.22, 
P=0.0034) (Fig. 5A) and type II (24 h, 0.54±0.08, P<0.0001; 
48 h, 0.70±0.08, P=0.008; 72 h, 0.50±0.24, P=0.24) (Fig. 5B), 
compared to control treated cells given as 1.0. Furthermore, 
the TGFβ intracellular downstream signaling proteins Smad3 
(24 h, 0.53±0.18, P=0.0096; 48 h, 0.49±0.12, P<0.0001; 72 h, 
0.27±0.07, P<0.0001) (Fig. 5C) and Smad4 (72 h, 0.56±0.28, 
P=0.0071) (Fig. 5D) were significantly suppressed. Moreover, 
alterations of survivin, cyclin-dependent kinase inhibitor 1 
(p21), caspase-3 and Bcl-2-associated X protein (Bax) mRNA 
levels were verified by quantitative RT-PCR and normalized 
to control cells. During propagation of PC-3 cells in the pres-
ence of 30 µM abiraterone, the expression of the anti-apoptotic 
cell survival factor survivin was suppressed (24 h, 0.33±0.40, 
P=0.0438; 48 h, 1.01±1.05; 72 h, 0.25±0.08, P<0.0001) (Fig. 6A). 
Accordingly, mRNA levels of the pro-apoptotic regulators p21 
(24 h, 1.56±2.26; 48 h, 4.00±1.52, P=0.0269; 72 h, 5.19±2.20, 
P=0.0088) (Fig. 6B) and caspase-3 (24 h, 5.62±2.63, P=0.0382; 
48 h, 4.08±4.84; 72 h, 1.02±0.69) (Fig. 6C) were significantly 
elevated. Notably, synthesis of the pro-oncogenic factor Bax 
was slightly but significantly reduced within 72 h of abiraterone 
incubation (24 h, 1.11±0.55; 48 h, 1.00±0.82; 72 h, 0.37±0.09, 
P<0.0001) (Fig. 6D).
Discussion
Molecular properties of CYP17A1 as a key enzyme in 
androgen biosynthesis provided the rationale for development 
of the CYP17A1 inhibitor abiraterone. Former studies with 
regard to the multiple cytochrome P450 enzyme inhibitor 
ketoconazole have served as proof-of-principle: repression of 
Figure 3. Abiraterone (AA) treatment attenuates cell growth of AR-negative PC-3 cells. (A) PC-3 cell were treated with vehicle or with concentrations of 10, 
20, 30 and 40 µM abiraterone and proliferation assays were performed after indicated times of incubation. Columns, mean; bars, ± SD; *P≤0.05, **P≤0.01 and 
***P≤0.001 (compared to vehicle treated control cells). (B) PC-3 cells were treated with vehicle or with 30 µM abiraterone for a period of time of 120 h and pro-
liferation assays were performed after indicated times of incubation. Boxes, mean; bars, ± SD; *P≤0.05, **P≤0.01 and ***P≤0.001 (total number of living cells).
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Figure 4. Abiraterone (AA) treatment is followed by induction of apoptosis. (A and B) PC-3 cells were treated with vehicle or with 30 µM abiraterone for the 
indicated time-points and were stained with propidium iodide and FITC Annexin V. Data were assessed by a FACSCanto A Cytometer. (C) PC-3 cells were 
treated with vehicle or with 30 µM abiraterone for the indicated time-points. Docetaxel of 10 nM treated PC-3 cells served as control. Unlabeled control cells 
served as negative control and nuclease treated cells as positive control, respectively. Cells were harvested and processed by specific labeling of nuclear DNA 
fragmentation with a HT TiterTACS assay kit. Data are expressed as the mean ± SD (compared and normalized to vehicle treated control cells). *p<0.05 and 
***p<0.001, as determined by Student's t-test.
Figure 5. Abiraterone diminishes factors of the TGFβ signaling pathway. (A-D) PC-3 cells were treated with vehicle or with 30 µM abiraterone for the indicated 
duration and total cell extracts were subjected to western blot analyses normalized to GAPDH as internal reference. (A) TGFβ receptor I; (B) TGFβ receptor II; 
(C) Smad3; (D) Smad4. Columns, mean; bars, ± SD; *P≤0.05, **P≤0.01 and ***P≤0.001 (compared to vehicle treated control cells).
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cytochrome P450 enzymes including CYP17A1 were shown 
to harbor anticancer activity in PC, however, ketoconazole 
administration was of minor benefit and was accompanied 
by significant toxicity (13). Recent studies of Brossard et al 
utilizing abiraterone derivates with a broad spectrum of 
inhibited cytochrome P450 enzymes have confirmed this 
hypothesis (14). Therefore, current understanding of molecular 
abiraterone efficacy in PC is primarily based on attenuated 
androgen biosynthesis/conversion and subsequent diminished 
AR signaling by the potent and specific inhibition of CYP17A1.
The data presented here provide evidence that abiraterone 
treatment resulted in significantly reduced proliferation rates 
even for PC cells lacking AR signaling. We previously reported 
that abiraterone significantly decreased the viability of AR 
expressing LNCaP cells most likely by the antagonistic prop-
erties of abiraterone (7,8). Moreover, growth attenuation was 
accompanied by a dramatically diminshed AR protein expres-
sion and activity. These observations are in accordance with a 
study of Soifer et al, which considered downregulation of the 
AR in the presence of 1.0-15.0 µM abiraterone (15).
Remarkably, AR-negative PC-3 cells exhibited comparably 
inhibited growth characteristics in the presence of abiraterone. 
The applied drug concentration of 30 µM corresponds to 
abiraterone concentrations which were determined in our 
study (10 µM in LNCaP cell incubation experiments) and in 
a study of Bruno et al (10 µM in PC-3 cell incubation experi-
ments) (16). Notably, attenuation of PC-3 proliferation point to 
additional and AR-independent pathways which were targeted 
by abiraterone. Accordingly, further experiments suggested 
a broad spectrum of anti-tumor activities of abiraterone 
displayed by targeting regulatory factors of TGFβ, apoptosis 
and cell cycle pathways.
Besides the numerous AR signaling events, it is well estab-
lished that there are several proliferative signal cascades which 
are qualified to become active in PC growth, e.g. phosphati-
dylinositide 3-kinase (17), epidermal growth factor (18), and 
estrogen receptor (19) pathways. The precise role of the pleio-
tropic growth factor TGFβ, which is also part of this multiple 
and fine-tuned regulatory network, is controversial. On the 
one hand, TGFβ has been reported to govern differentiation 
and anti-proliferation in non-malignant prostate epithelium 
as well as in early stage PC tissue. On the other hand, TGFβ 
signals are linked to a tumorigenic phenotype in advanced 
PC stages (20-23). Even though abiraterone did not affect 
TGFβ1 and TGFβ2 mRNA levels (data not shown), analysis of 
TGFβ pathway proteins revealed a clear suppression of TGFβ 
cascades. Abiraterone inhibited both types of TGFβ receptors, 
type I and II, as well as the downstream signaling molecules 
Smad3 and Smad4; thus, it is reasonable to hypothesize a 
strong reduction of TGFβ signaling by abiraterone treatment. 
However, since TGFβ signals play a dual role in PC reflected 
by its opposing properties of pro- and anti-oncogenic effects, 
it is difficult to estimate the TGFβ-dependent impact of 
abiraterone. Though, elevated serum levels of TGFβ have been 
shown to predict tumor recurrence and metastasis, and the PC 
cells became less responsive to TGFβ growth inhibition in 
later stages of PC (20,24), therefore, abiraterone efficacy was 
probably due to attenuation of TGFβ-dependent oncogenic 
Figure 6. Abiraterone suppresses factors of apoptosis and cell cycle pathways. (A-D) PC-3 cells were treated with vehicle or with 30 µM abiraterone for the 
indicated duration and specific transcripts were quantified by performing quantitative RT-PCR with RPLP0 mRNA as internal reference. (A) Survivin mRNA; 
(B) p21 mRNA; (C) caspase-3 mRNA; (D) Bax mRNA. Columns, mean; bars, ± SD; *P≤0.05, **P≤0.01 and ***P≤0.001 (compared to vehicle treated control cells).
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signal cascades. However, these results further exemplify the 
difficulties of interpretation of TGFβ pathways in PC cell 
biology and may suggest further investigations in this field.
Chemotherapy widely exerts its anticancer effect by 
triggering apoptotic mechanisms of tumor cells. A primary 
regulator of apoptosis is the tumor suppressor p53, which plays 
a key role in cell cycle control, genomic stability, and apoptosis. 
Due to a frame shift within the p53 gene, PC-3 cells express 
a truncated and therefore inactive form of the protein (25,26), 
however, the induction of apoptosis pathways in absence 
of p53 as a response to drug treatment has been extensively 
described (27-29). Notwithstanding, in PC-3 cells lacking 
functional p53 the initiation of intrinsic apoptosis pathway 
factors occurs in the presence of abiraterone. Increased 
DNA fragmentation as determined by TUNEL assay, as well 
as downregulation of the cell survival factor survivin and 
elevated levels of the cell cycle inhibitor p21 and the effector 
caspase-3 clearly indicated an execution of apoptotic mecha-
nisms. These data confirm former studies which have shown 
that anticancer drugs affect the biosynthesis of these intrinsic 
apoptotic factors in PC-3 cells (28,30-32). Surprisingly, our 
results could not be definitely verified by Annexin V staining. 
Since externalisation of Annexin V to the outer plasma 
membrane is a very early effect in apoptosis, it could be specu-
lated that Annexin V signals have already expired before the 
first selected time point. However, it is notable that Annexin V 
staining of PC-3 cells failed also previously (33). Curiously, 
we monitored significantly reduced levels of pro-apoptotic 
Bax after 72 h of abiraterone incubation. This finding is not 
consistent with earlier reports in which Bax has been shown 
being drug-induced in PC-3 cells (28). The intrinsic apoptosis 
pathway is controlled by a balance of pro-apoptotic (e.g. Bax, 
p21 and caspase-3) and anti-apoptotic (e.g. survivin) factors. 
Apoptosis in the absence of p53, however, appears complex. 
Therefore, differing cell death cascades compared to the clas-
sical intrinsic apoptosis pathways by interfering with other 
regulatory pathways may occur. For instance, there have been 
reports that apoptosis induced by the hypoxia response system 
can provoke a downregulation of Bax in cancer cells (34,35).
Taken together, our observations suggest that abiraterone-
mediated attenuation of AR signals is not the only rationale 
to explain anticancer activity. Besides an expected inhibition 
of LNCaP cell growth by targeting the AR, very notably, 
abiraterone comparably inhibited proliferation of AR-negative 
PC-3 cells. Thus, abiraterone's molecular mode of action is 
proposed to be mediated through an accessory inhibition of 
pro-oncogenic TGFβ signals and through the alteration of 
apoptotic factors.
Experimental and preclinical data continue to enlarge our 
understanding of abiraterone molecular mode of action and 
facilitate the opportunity to improve PC treatment regimes as 
well as to overcome resistance to abiraterone. Interestingly, 
current data showed no, or no detectable expression of 
CYP17A1 enzyme in LNCaP and PC-3 cell lines (35) and, 
in this context, abiraterone efficacy may play a more global 
role in PC progression control than originally hypothesized. 
Consequently, abiraterone is not only a promising drug for 
treatment of AR-negative PC stages, even more, abiraterone 
may represent a therapeutical alternative for treatment of other 
malignancies besides PC.
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